40469-00-9

Basic information

• Product Name: 3-Buten-2-one, 4-(5-bromo-2-hydroxyphenyl)-
• CAS NO: 40469-00-9
• Molecular Formula: C10H9BrO2
• Molecular Weight: 241.084
• Mol File: 40469-00-9.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: 3-Buten-2-one, 4-(5-bromo-2-hydroxyphenyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Buten-2-one, 4-(5-bromo-2-hydroxyphenyl)-(40469-00-9)
• EPA Substance Registry System: 3-Buten-2-one, 4-(5-bromo-2-hydroxyphenyl)-(40469-00-9)

Safety Data

• Hazardous Substances Data: 40469-00-9(Hazardous Substances Data)

Upstream product

• 67-64-1 acetone 
• 1761-61-1 5-bromosalicyclaldehyde 

Downstream Products

• 123302-63-6 4-Bromo-2-((E)-2-[1,8]naphthyridin-2-yl-vinyl)-phenol 
• 119607-67-9 (1E,4E)-1-(5-Bromo-2-hydroxy-phenyl)-5-(9-ethyl-9H-carbazol-3-yl)-penta-1,4-dien-3-one 
• 1620753-67-4 4-bromo-2-(3-methyl-1-((4-(trifluoromethyl)phenyl)sulfonyl)-4,5-dihydro-1H-pyrazol-5-yl)phenol 
• 1608479-25-9 6-bromo-3-methyl-1-phenylbenzofuro[2,3-c]pyridine 
• 1620753-59-4 4-bromo-2-(3-methyl-4,5-dihydro-1H-pyrazol-5-yl)phenol 
• 1620753-68-5 4-bromo-2-(1-((2-iodophenyl)sulfonyl)-3-methyl-4,5-dihydro-1H-pyrazol-5-yl)phenol 
• 1620753-66-3 4-bromo-2-(1-((4-methoxyphenyl)sulfonyl)-3-methyl-4,5-dihydro-1H-pyrazol-5-yl)phenol 
• 1620753-65-2 4-bromo-2-(1-((2,4-dichlorophenyl)sulfonyl)-3-methyl-4,5-dihydro-1H-pyrazol-5-yl)phenol 
• 1620753-64-1 4-bromo-2-(1-((4-chlorophenyl)sulfonyl)-3-methyl-4,5-dihydro-1H-pyrazol-5-yl)phenol 
• 1620753-63-0 4-bromo-2-(1-((4-fluorophenyl)sulfonyl)-3-methyl-4,5-dihydro-1H-pyrazol-5-yl)phenol 

Relevant articles and documents

Tricyclic pyrazolo[1,5-d][1,4]benzoxazepin-5(6H)-one scaffold derivatives: Synthesis and biological evaluation as selective BuChE inhibitors

BuChE inhibitors play important roles in treatment of patients with advanced Alzheimer's disease (AD). A series of tricyclic pyrazolo[1,5-d][1,4]benzoxazepin-5(6H)-one derivatives were synthesized and evaluated as acetylcholinesterase (AChE) and butyrylch

Dihydropyrazole derivatives as telomerase inhibitors: Structure-based design, synthesis, SAR and anticancer evaluation in vitro and in vivo

It is of our interest to generate and identify novel compounds with regulation telomerase for cancer therapy. In order to carry out more rational design, based on structure-based drug design, several series of N-substituted-dihydropyrazole derivatives, totally 78 compounds as potential human telomerase inhibitors were designed and synthesized. The results demonstrated that some compounds had potent anticancer activity against four tumor cell lines, and showed good selectivity on tumor cells over somatic cells. By the modified TRAP assay, compound 13i exhibited the most potent inhibitory activity against telomerase with an IC50 value of 0.98 μM. In vivo evaluation results indicated that compound 13i could inhibit growth of S180 and HepG2 tumor-bearing mice, and it also significantly enhanced the survival rate of EAC tumor-bearing mice. The further results in vivo confirmed that it could significantly improve pathological changes of N,N-diethylnitrosamine (DEN)-induced rat hepatic tumor. These data support further studies to assess rational design of more efficient telomerase inhibitors in the future.

Novel 4-bromo-2-(3-methyl-1-(substituted-phenylsulfonyl)-4,5-dihydro-1-H- pyrazol-5-yl)phenol derivatives: Synthesis and antibacterial activity

A series of novel 4-bromo-2-(3-methyl-1-(substituted-phenylsulfonyl)-4,5- dihydro-1H-pyrazol-5-yl) phenol derivatives were synthesized and characterized by NMR, ESI-MS. Compound 3c was determined by X-ray. Biological activity tests results show that compound 3h displayed activity with MIC of 0.39, 0.78, 1.562 μg/mL against B. subtilis ATCC 6633, S. aureus ATCC 6538, P. fluorescens ATCC 13525 and could strongly inhibit S. aureus DNA gyrase and B. subtilis DNA gyrase with IC50s of 0.25 and 0.18 μg/mL respectively.